ScholarIQanswers from OpenAlex & ORCID
Shengxiang Ren
ResearcherPublications, citations & collaboration network
Shengxiang Ren is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Shengxiang Ren have?
ScholarIQindexed works
Shengxiang Ren has 366 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Shengxiang Ren have?
ScholarIQcitation count
Shengxiang Ren has 17,103 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Shengxiang Ren?
ScholarIQh-index
Shengxiang Ren has an h-index of 60 in OpenAlex.
What is the i10-index of Shengxiang Ren?
ScholarIQi10-index
Shengxiang Ren has an i10-index of 191 in OpenAlex.
What is the ORCID of Shengxiang Ren?
ScholarIQorcid
The ORCID for Shengxiang Ren is on the source record.
What is the OpenAlex record for Shengxiang Ren?
ScholarIQopenalex
The OpenAlex for Shengxiang Ren is on the source record.
What are the most-cited papers on Shengxiang Ren?
ScholarIQmost cited works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Role of IL-2 in cancer immunotherapy
Tao Jiang, Caicun Zhou, Shengxiang Ren
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou, Yi‐Long Wu, G. Chen, J. Feng, Xuetong Liu, C. Wang, S. Zhang, J. Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, L. Zhang, Chengping Hu, Chengping Hu, Yi Luo, Lin Chen, M. Ye, Juanjuan Huang, X. Zhi, Y. Zhang, Qingyu Xiu, W. F. Mader, L. Zhang, Changxuan You
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao, Shengxiang Ren, Tao Jiang, Bo Zhu, Xuefei Li, Chao Zhao, Yijun Jia, Jinpeng Shi, Limin Zhang, Xiaozhen Liu, Meng Qiao, Xiaoxia Chen, Chunxia Su, Hui Yu, Caicun Zhou, Jun Zhang, D. Ross Camidge, Fred R. Hirsch
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Shengxiang Ren, Jianhua Chen, Xingxiang Xu, Tao Jiang, Ying Cheng, Gongyan Chen, Yueyin Pan, Yong Fang, Qiming Wang, Yunchao Huang, Wenxiu Yao, Rui Wang, Xingya Li, Wei Zhang, Yanjun Zhang, Sheng Hu, Renhua Guo, Jianhua Shi, Zhiwu Wang, Peiguo Cao, Donglin Wang, Jian Fang, Hui Luo, Yi Geng, Chunyan Xing, Dongqing Lv, Yiping Zhang, Junyan Yu, Shundong Cang, Zeyu Yang, Wei Shi, Jianjun Zou, Caicun Zhou